I bet FY24 NPATA growth gradually gets upgraded throughout the year to circa 20% yoy at constant currency . Sales are growing double digits and there are many levers to improve margins as volumes pickup. Csl is firing on all cylinders. With garadacimab as icing on top
I bet FY24 NPATA growth gradually gets upgraded throughout the...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$280.00 |
Change
-6.950(2.42%) |
Mkt cap ! $135.3B | |||
| Open | High | Low | Value | Volume |
| $285.50 | $285.54 | $279.66 | $396.2M | 1.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 337 | $279.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $280.00 | 23597 | 7 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$279.98 |
Change
-6.950 ( 2.34 %) |
||||
| Open | High | Low | Volume | ||
| $285.34 | $285.52 | $279.66 | 178512 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| CSL (ASX) Chart |